Chronic kidney disease growth factors in renal fibrosis

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 7, 2011, Pages 441-450

  Boor, Peter ^a,b   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b Physics and Informatics   (Slovakia)

Author keywords

Bone morphogenic protein 7; Connective tissue growth factor; Growth factors; Platelet derived growth factor; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; GROWTH FACTOR; IMATINIB; MITOGENIC AGENT; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENZYME INHIBITION; FIBROBLAST; FIBROGENESIS; HUMAN; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LEUKOCYTE; MACROPHAGE; MITOGENESIS; MYOFIBROBLAST; NONHUMAN; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 79959702777     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05487.x     Document Type: Review

References (96)

1. Boor P, Sebekova K, Ostendorf T, Floege J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant. 2007; 22: 3391-407.
2. Boor P, Ostendorf T, Floege J. Renal fibrosis - novel insights into mechanisms and therapeutic targets. Nat. Rev. Nephrol. 2010; 6: 643-56.
3. Boor P, Kunter U. Polyclonal immunoglobulin G ameliorates the course of progressive mesangioproliferative glomerulonephritis in rats. Kidney Blood Press. Res. 2009; 32: 169-74.
4. Eitner F, Floege J. Therapeutic targets for prevention and regression of progressive fibrosing renal diseases. Curr. Opin. Investig. Drugs 2005; 6: 255-61.
5. Bottinger EP, Bitzer M. TGF-beta signaling in renal disease. J. Am. Soc. Nephrol. 2002; 13: 2600-10.
6. Yu L, Border WA, Huang Y, Noble NA. TGF-beta isoforms in renal fibrogenesis. Kidney Int. 2003; 64: 844-56.
7. Huang XR, Chung AC, Wang XJ, Lai KN, Lan HY. Mice overexpressing latent TGFbeta1 are protected against renal fibrosis in obstructive kidney disease. Am. J. Physiol. Renal Physiol. 2008; 295: F118-27.
8. Huang XR, Chung AC, Zhou L, Wang XJ, Lan HY. Latent TGF-beta1 protects against crescentic glomerulonephritis. J. Am. Soc. Nephrol. 2008; 19: 233-42.
9. Koesters R, Kaissling B, Lehir M et al. Tubular overexpression of transforming growth factor-beta1 induces autophagy and fibrosis but not mesenchymal transition of renal epithelial cells. Am. J. Pathol. 2010; 177: 632-43.
10. Shull MM, Ormsby I, Kier AB et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-9.
11. Terada Y, Hanada S, Nakao A, Kuwahara M, Sasaki S, Marumo F. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int. 2002; 61: 94-8.
12. Lan HY, Mu W, Tomita N et al. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J. Am. Soc. Nephrol. 2003; 14: 1535-48.
13. Hou CC, Wang W, Huang XR et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am. J. Pathol. 2005; 166: 761-71.
14. Inazaki K, Kanamaru Y, Kojima Y et al. Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. Kidney Int. 2004; 66: 597-604.
15. Sato M, Muragaki Y, Saika S, Roberts AB, Ooshima A. Targeted disruption of TGFbeta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J. Clin. Invest. 2003; 112: 1486-94.
16. Meng XM, Huang XR, Chung AC et al. Smad2 protects against TGF-beta/Smad3-mediated renal fibrosis. J. Am. Soc. Nephrol. 2010; 21: 1477-87.
17. Fukasawa H, Yamamoto T, Togawa A et al. Ubiquitin-dependent degradation of SnoN and Ski is increased in renal fibrosis induced by obstructive injury. Kidney Int. 2006; 69: 1733-40.
18. Yang J, Zhang X, Li Y, Liu Y. Downregulation of Smad transcriptional corepressors SnoN and Ski in the fibrotic kidney: An amplification mechanism for TGF-beta1 signaling. J. Am. Soc. Nephrol. 2003; 14: 3167-77.
19. Moon JA, Kim HT, Cho IS, Sheen YY, Kim DK. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 2006; 70: 1234-43.
20. Grygielko ET, Martin WM, Tweed C et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factorbeta type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. 2005; 313: 943-51.
21. Li J, Campanale NV, Liang RJ, Deane JA, Bertram JF, Ricardo SD. Inhibition of p38 mitogen-activated protein kinase and transforming growth factor-beta1/Smad signaling pathways modulates the development of fibrosis in adriamycin-induced nephropathy. Am. J. Pathol. 2006; 169: 1527-40.
22. Prakash J, Sandovici M, Saluja V et al. Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular cells: A novel strategy to treat renal fibrosis. J. Pharmacol. Exp. Ther. 2006; 319: 8-19.
23. Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ. The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J. Am. Soc. Nephrol. 2004; 15: 370-9.
24. Schaefer L, Macakova K, Raslik I et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am. J. Pathol. 2002; 160: 1181-91.
25. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat. Med. 1996; 2: 418-23.
26. Krupa A, Jenkins R, Luo DD, Lewis A, Phillips A, Fraser D. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 2010; 21: 438-47.
27. Kato M, Zhang J, Wang M et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U S A 2007; 104: 3432-7.
28. Chung AC, Huang XR, Meng X, Lan HY. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. J. Am. Soc. Nephrol. 2010; 21: 1317-25.
29. Suthanthiran M, Gerber LM, Schwartz JE et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int. 2009; 76: 72-80.
30. August P, Suthanthiran M. Transforming growth factor beta and progression of renal disease. Kidney Int. Suppl. 2003; 87: S99-104.
31. Brabcova I, Tesar V, Honsova E et al. Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression. Nephrol. Dial. Transplant. 2011; 26: 573-79.
32. Li B, Khanna A, Sharma V, Singh T, Suthanthiran M, August P. TGF-beta1 DNA polymorphisms, protein levels, and blood pressure. Hypertension 1999; 33: 271-5.
33. Zeisberg M. Bone morphogenic protein-7 and the kidney: Current concepts and open questions. Nephrol. Dial. Transplant. 2006; 21: 568-73.
34. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 2008; 19: 2098-107.
35. Zeisberg M, Hanai J, Sugimoto H et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 2003; 9: 964-8.
36. Zeisberg M, Bottiglio C, Kumar N et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 2003; 285: F1060-7.
37. Zeisberg M, Shah AA, Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 2005; 280: 8094-100.
38. Hruska KA, Guo G, Wozniak M et al. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am. J. Physiol. Renal Physiol. 2000; 279: F130-43.
39. Wang S, Chen Q, Simon TC et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 2003; 63: 2037-49.
40. Li T, Surendran K, Zawaideh MA, Mathew S, Hruska KA. Bone morphogenetic protein 7: A novel treatment for chronic renal and bone disease. Curr. Opin. Nephrol. Hypertens. 2004; 13: 417-22.
41. Lin J, Patel SR, Cheng X et al. Kielin/chordin-like protein, a novel enhancer of BMP signaling, attenuates renal fibrotic disease. Nat. Med. 2005; 11: 387-93.
42. Yanagita M. Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int. 2006; 70: 989-93.
43. Tanaka M, Asada M, Higashi AY et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J. Clin. Invest. 2010; 120: 768-77.
44. Phanish MK, Winn SK, Dockrell ME. Connective tissue growth factor-(CTGF, CCN2) - a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp. Nephrol. 2010; 114: e83-92.
45. Riser BL, Najmabadi F, Perbal B et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am. J. Pathol. 2009; 174: 1725-34.
46. Riser BL, Najmabadi F, Perbal B et al. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J. Cell Commun. Signal. 2010; 4: 39-50.
47. van Roeyen CR, Eitner F, Scholl T et al. CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferation. Kidney Int. 2008; 73: 86-94.
48. Abdel Wahab N, Mason RM. Connective tissue growth factor and renal diseases: Some answers, more questions. Curr. Opin. Nephrol. Hypertens. 2004; 13: 53-8.
49. Burns WC, Twigg SM, Forbes JM et al. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: Implications for diabetic renal disease. J. Am. Soc. Nephrol. 2006; 17: 2484-94.
50. Okada H, Kikuta T, Kobayashi T et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J. Am. Soc. Nephrol. 2005; 16: 133-43.
51. van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R. Imbalance of growth factor signalling in diabetic kidney disease: Is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol. Dial. Transplant. 2005; 20: 6-10.
52. Yokoi H, Mukoyama M, Nagae T et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 2004; 15: 1430-40.
53. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor betaindependent pathway. Am. J. Pathol. 2004; 165: 2033-43.
54. Nguyen TQ, Tarnow L, Jorsal A et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008; 31: 1177-82.
55. Jaffa AA, Usinger WR, McHenry MB et al. Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes. J. Clin. Endocrinol. Metab. 2008; 93: 1893-900.
56. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004; 15: 255-73.
57. Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 2008; 19: 12-23.
58. Ostendorf T, Kunter U, Grone HJ et al. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 2001; 12: 909-18.
59. Tang WW, Ulich TR, Lacey DL et al. Platelet-derived growth factor-BB induces renal tubulointerstitial myofibroblast formation and tubulointerstitial fibrosis. Am. J. Pathol. 1996; 148: 1169-80.
60. Taneda S, Hudkins KL, Topouzis S et al. Obstructive uropathy in mice and humans: Potential role for PDGF-D in the progression of tubulointerstitial injury. J. Am. Soc. Nephrol. 2003; 14: 2544-55.
61. Hudkins KL, Gilbertson DG, Carling M et al. Exogenous PDGF-D is a potent mesangial cell mitogen and causes a severe mesangial proliferative glomerulopathy. J. Am. Soc. Nephrol. 2004; 15: 286-98.
62. Ostendorf T, van Roeyen CR, Peterson JD et al. A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 2003; 14: 2237-47.
63. Ostendorf T, Rong S, Boor P et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 2006; 17: 1054-62.
64. Boor P, Konieczny A, Villa L et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol. Dial. Transplant. 2007; 22: 1323-31.
65. Boor P, Eitner F, Cohen CD et al. Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. Nephrol. Dial. Transplant. 2009; 24: 2755-62.
66. Rong ZH, Wang C, Hao J, Duan HJ. [Expression and clinical implication of plateletderived growth factor-D and platelet-derived growth factor-beta in childhood IgA nephropathy]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2008; 20: 275-8.
67. Cianciolo G, Stefoni S, Zanchelli F et al. PDGF-AB release during and after haemodialysis procedure. Nephrol. Dial. Transplant. 1999; 14: 2413-19.
68. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J. Am. Soc. Nephrol. 1997; 8: 1147-56.
69. Eitner F, Ostendorf T, Kretzler M et al. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J. Am. Soc. Nephrol. 2003; 14: 1145-53.
70. Eitner F, Ostendorf T, Van Roeyen C et al. Expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J. Am. Soc. Nephrol. 2002; 13: 910-17.
71. Kishioka H, Fukuda N, Wen-Yang H, Nakayama M, Watanabe Y, Kanmatsuse K. Effects of PDGF A-chain antisense oligodeoxynucleotides on growth of cardiovascular organs in stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 2001; 14: 439-45.
72. Eitner F, Bucher E, van Roeyen C et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J. Am. Soc. Nephrol. 2008; 19: 281-9.
73. Boor P, van Roeyen CR, Kunter U et al. PDGF-C mediates glomerular capillary repair. Am. J. Pathol. 2010; 177: 58-69.
74. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J. 2005; 19: 1-11.
75. Lassila M, Jandeleit-Dahm K, Seah KK et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J. Am. Soc. Nephrol. 2005; 16: 363-73.
76. Savikko J, Taskinen E, Von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: Tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147-53.
77. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006; 12: 908-16.
78. Berman E, Nicolaides M, Maki RG et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N. Engl. J. Med. 2006; 354: 2006-13.
79. Eremina V, Baelde HJ, Quaggin SE. Role of the VEGF - a signaling pathway in the glomerulus: Evidence for crosstalk between components of the glomerular filtration barrier. Nephron Physiol. 2007; 106: p32-7.
80. Nangaku M. Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure. J. Am. Soc. Nephrol. 2006; 17: 17-25.
81. Lerman LO, Chade AR. Angiogenesis in the kidney: A new therapeutic target? Curr. Opin. Nephrol. Hypertens. 2009; 18: 160-5.
82. Kang DH, Johnson RJ. Vascular endothelial growth factor: A new player in the pathogenesis of renal fibrosis. Curr. Opin. Nephrol. Hypertens. 2003; 12: 43-9.
83. Kang DH, Hughes J, Mazzali M, Schreiner GF, Johnson RJ. Impaired angiogenesis in the remnant kidney model: II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J. Am. Soc. Nephrol. 2001; 12: 1448-57.
84. Kang DH, Kim YG, Andoh TF et al. Post-cyclosporine-mediated hypertension and nephropathy: Amelioration by vascular endothelial growth factor. Am. J. Physiol. Renal Physiol. 2001; 280: F727-36.
85. de Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J. Am. Soc. Nephrol. 2001; 12: 993-1000.
86. Schrijvers BF, Flyvbjerg A, Tilton RG, Rasch R, Lameire NH, De Vriese AS. Pathophysiological role of vascular endothelial growth factor in the remnant kidney. Nephron Exp. Nephrol. 2005; 101: e9-15.
87. Schrijvers BF, Rasch R, Tilton RG, Flyvbjerg A. High protein-induced glomerular hypertrophy is vascular endothelial growth factor-dependent. Kidney Int. 2002; 61: 1600-4.
88. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 2002; 51: 3090-4.
89. Leonard EC, Friedrich JL, Basile DP. VEGF-121 preserves renal microvessel structure and ameliorates secondary renal disease following acute kidney injury. Am J Physiol RenalPhysiol. 2008; 295: F1648-57.
90. Hakroush S, Moeller MJ, Theilig F et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am. J. Pathol. 2009; 175: 1883-95.
91. Mu W, Long DA, Ouyang X et al. Angiostatin overexpression is associated with an improvement in chronic kidney injury by an anti-inflammatory mechanism. Am. J. Physiol. Renal Physiol. 2009; 296: F145-52.
92. Sakamoto I, Ito Y, Mizuno M et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int. 2009; 75: 828-38.
93. Matsui K, Nagy-Bojarsky K, Laakkonen P et al. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: Aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J. Am. Soc. Nephrol. 2003; 14: 1981-9.
94. Zhang T, Guan G, Liu G et al. Disturbance of lymph circulation develops renal fibrosis in rats with or without contralateral nephrectomy. Nephrology (Carlton) 2008; 13: 128-38.
95. Zhang T, Liu G, Sun M, Guan G, Chen B, Li X. Functional, histological and biochemical consequences of renal lymph disorder in mononephrectomized rats. J. Nephrol. 2009; 22: 109-16.
96. Hawthorne T, Giot L, Blake L et al. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int. J. Clin. Pharmacol. Ther. 2008; 46: 236-44.